Afimoxifene
Afimoxifene is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target estrogen receptor, estrogen receptor beta, estrogen-related receptor gamma, and G-protein coupled estrogen receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast density | D000071060 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 6 | — | — | 1 | 7 |
| Carcinoma | D002277 | — | C80.0 | — | 4 | — | — | — | 4 |
| Carcinoma in situ | D002278 | — | D09.9 | — | 4 | — | — | — | 4 |
| Breast carcinoma in situ | D000071960 | — | D05 | — | 4 | — | — | — | 4 |
| Ductal carcinoma breast | D018270 | — | — | — | 3 | — | — | — | 3 |
| Intraductal carcinoma noninfiltrating | D002285 | — | D05.1 | — | 3 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | — | 2 | — | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Lobular carcinoma | D018275 | EFO_0000570 | — | — | 1 | — | — | — | 1 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Afimoxifene |
| INN | afimoxifene |
| Description | Afimoxifene is a tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen. It has a role as an antineoplastic agent, an estrogen receptor antagonist and a metabolite. It is a tertiary amino compound and a member of phenols. It is functionally related to a tamoxifen. |
| Classification | Small molecule |
| Drug class | antiestrogens of the clomifene and tamoxifen groups |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC/C(=C(\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 68392-35-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL489 |
| ChEBI ID | 44616 |
| PubChem CID | 449459 |
| DrugBank | — |
| UNII ID | 17197F0KYM (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ESR1
ESR1
ESR2
ESR2
ESRRG
ESRRG
GPER1
GPER1
Organism
Homo sapiens
Gene name
ESR1
Gene synonyms
ESR, NR3A1
NCBI Gene ID
Protein name
estrogen receptor
Protein synonyms
E2 receptor alpha, ER-alpha, Estradiol receptor, estrogen nuclear receptor alpha, estrogen receptor alpha E1-E2-1-2, estrogen receptor alpha E1-N2-E2-1-2, Nuclear receptor subfamily 3 group A member 1, oestrogen receptor alpha
Uniprot ID
Mouse ortholog
Esr1 (13982)
estrogen receptor (Q9QY52)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,584 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use